Today, Taimei Medical Technology debuted on the Hong Kong stock market and immediately broke. The issue price was 13.00 Hong Kong dollars per share, and the closing price was 9.20 Hong Kong dollars per share, a 30% break. After being rejected for listing on the STAR Market, Taimei Medical Technology quickly turned to the Hong Kong stock market, but a series of operational issues that led to its rejection remain unresolved. In recent years, Taimei Medical Technology's revenue growth has clearly slowed down and continues to be in a loss. Not only has the company's employees scale significantly decreased compared to before, but the customer base continues to decline. The company's ability to collect payments has decreased, and in recent years, operating cash flow has been consistently negative, making it difficult to have its own "blood-making" ability.